Prathima Nandivada1, Lorenzo Anez-Bustillos1, Alison A O'Loughlin1, Paul D Mitchell2, Meredith A Baker1, Duy T Dao1, Gillian L Fell1, Alexis K Potemkin1, Kathleen M Gura3, Ellis J Neufeld4, Mark Puder5. 1. Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA. 2. Clinical Research Center, Biostatistics Core, Boston Children's Hospital, Boston, MA, USA. 3. Department of Pharmacy, Boston Children's Hospital, Boston, MA, USA. 4. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. 5. Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA. Electronic address: mark.puder@childrens.harvard.edu.
Abstract
BACKGROUND: Intestinal failure-associated liver disease (IFALD) can be treated with parenteral fish oil (FO) monotherapy, but practitioners have raised concerns about a potential bleeding risk. This study aims to describe the incidence of clinically significant post-procedural bleeding (CSPPB) in children receiving FO monotherapy. METHODS: A retrospective chart review was performed on patients at our institution treated with intravenous FO for IFALD. CSPPB was defined as bleeding leading to re-operation, transfer to the intensive care unit, re-admission, or death, up to one month after any invasive procedure. RESULTS: From 244 patients reviewed, 183 underwent ≥1 invasive procedure(s) (n = 732). Five (0.68%, 95% CI 0.22-1.59%) procedures resulted in CSPPB. FO therapy was never interrupted. No deaths due to bleeding occurred. CONCLUSIONS: Findings suggest that FO therapy is safe, with a CSPPB risk no greater than that reported in the general population. O3FA should not be held in preparation for procedures or in the event of bleeding.
BACKGROUND:Intestinal failure-associated liver disease (IFALD) can be treated with parenteral fish oil (FO) monotherapy, but practitioners have raised concerns about a potential bleeding risk. This study aims to describe the incidence of clinically significant post-procedural bleeding (CSPPB) in children receiving FO monotherapy. METHODS: A retrospective chart review was performed on patients at our institution treated with intravenous FO for IFALD. CSPPB was defined as bleeding leading to re-operation, transfer to the intensive care unit, re-admission, or death, up to one month after any invasive procedure. RESULTS: From 244 patients reviewed, 183 underwent ≥1 invasive procedure(s) (n = 732). Five (0.68%, 95% CI 0.22-1.59%) procedures resulted in CSPPB. FO therapy was never interrupted. No deaths due to bleeding occurred. CONCLUSIONS: Findings suggest that FO therapy is safe, with a CSPPB risk no greater than that reported in the general population. O3FA should not be held in preparation for procedures or in the event of bleeding.
Authors: Faraz A Khan; Paul D Mitchell; Jeremy G Fisher; Eric A Sparks; Tom Jaksic; Christopher Duggan; Daniel H Teitelbaum; Biren P Modi Journal: J Pediatr Surg Date: 2014-11-14 Impact factor: 2.545
Authors: Mark K Larson; Garth W Tormoen; Lucinda J Weaver; Kristen J Luepke; Ishan A Patel; Carl E Hjelmen; Nicole M Ensz; Leah S McComas; Owen J T McCarty Journal: Am J Physiol Cell Physiol Date: 2012-11-21 Impact factor: 4.249
Authors: Margaret L Ong; Robert S Venick; Stephen B Shew; James C Y Dunn; Laurie Reyen; Tristan Grogan; Kara L Calkins Journal: JPEN J Parenter Enteral Nutr Date: 2019-03-22 Impact factor: 4.016
Authors: Szabolcs Péter; Gerjan Navis; Martin H de Borst; Clemens von Schacky; Anne Claire B van Orten-Luiten; Alexandra Zhernakova; Renger F Witkamp; André Janse; Peter Weber; Stephan J L Bakker; Manfred Eggersdorfer Journal: Eur J Nutr Date: 2017-08 Impact factor: 5.614